Literature DB >> 15607791

Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors.

Chiara Vitale1, Laura Chiossone, Giuseppe Morreale, Edoardo Lanino, Francesca Cottalasso, Sara Moretti, Giorgio Dini, Lorenzo Moretta, Maria Cristina Mingari.   

Abstract

Patients undergoing allogeneic bone marrow transplantation (BMT) offer a unique system to analyze the NK cell development in vivo. We analyzed NK cells from 24 such patients to assess the acquisition of activating receptors. Five patients displayed an immature NK cell surface phenotype at engraftment, as they were CD16(-), KIRs(-) and NKG2D(-) while expressed low levels of NKp46, NKp30, 2B4 and NKG2A. These NK cells had particularly low cytolytic activity against the HLA-class I-negative melanoma F01 cell line and the 721.221 Epstein-Barr virus (EBV)B-infected cells. Moreover, cytoxicity was inhibited upon mAb-mediated crosslinking of 2B4. Analysis of NK cells at day 30 after BMT revealed the occurrence of both phenotypic and functional maturation. These data are in agreement with a previous in vitro study showing that immature NK cell precursors express CD16, NKGD2 and killer Ig-like receptors (KIR) only at a late stage of differentiation and also express inhibitory 2B4. Remarkably, one of these patients did not display any phenotypic and functional maturation of NK cells and experienced a fatal post transplant EBV-related lymphoproliferative disease. Our present study allows a better understanding of the NK cell differentiation in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607791     DOI: 10.1016/j.molimm.2004.07.019

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  NKG2A and CD56 are coexpressed on activated TH2 but not TH1 lymphocytes.

Authors:  Robert J Freishtat; Lindsay W Mitchell; Svetlana D Ghimbovschi; Samuel B Meyers; Eric P Hoffman
Journal:  Hum Immunol       Date:  2006-03-27       Impact factor: 2.850

2.  Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity.

Authors:  Magloire Pandoua Nekoua; Antoine Bertin; Famara Sane; Enagnon Kazali Alidjinou; Delphine Lobert; Jacques Trauet; Christine Hober; Ilka Engelmann; Kabirou Moutairou; Akadiri Yessoufou; Didier Hober
Journal:  Cell Mol Life Sci       Date:  2019-06-06       Impact factor: 9.261

Review 3.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

4.  Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.

Authors:  B M Triplett; E M Horwitz; R Iyengar; V Turner; M S Holladay; K Gan; F G Behm; W Leung
Journal:  Leukemia       Date:  2009-02-12       Impact factor: 11.528

5.  Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.

Authors:  Gal Markel; Rachel Seidman; Michal J Besser; Naama Zabari; Rona Ortenberg; Ronnie Shapira; Avraham J Treves; Ron Loewenthal; Arie Orenstein; Arnon Nagler; Jacob Schachter
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

6.  The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.

Authors:  Isabel Y Pappworth; Eddie C Wang; Martin Rowe
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.

Authors:  Carolina Inés Domaica; Mercedes Beatriz Fuertes; Ignacio Uriarte; María Victoria Girart; Jessica Sardañons; Dorina Ileana Comas; Daniela Di Giovanni; María Isabel Gaillard; Liliana Bezrodnik; Norberto Walter Zwirner
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

8.  NKG2A inhibits TH2 cell effector function in vitro.

Authors:  Robert J Freishtat; Bahar Mojgani; Maryam Nazemzadeh; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  BMC Pulm Med       Date:  2007-10-10       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.